Healthcare >> CEO Interviews >> October 12, 2001
DR. RAYMOND P. WARRELL, JR., is Chairman of the Board and Chief
Executive Officer of Genta, Incorporated. Dr. Warrell is internationally
known for his expertise in the clinical development of anticancer
therapeutics. Prior to his appointment at Genta he was Associate
Physician-in-Chief and tenured Member of the Memorial Sloan-Kettering
Cancer Center. He was also Professor of Medicine at the Joan and Sanford
Weill Medical College of Cornell University. He has been a consultant to
a number of pharmaceutical and biotechnology companies, including Genta.
He is a co-Founder of PolaRx Biopharmaceuticals, Inc. (which developed
arsenic trioxide (Trisenox') for the treatment of acute promyelocytic
leukemia) and also of Relgen LLC, a privately held pharmaceutical
company. Dr. Warrell holds numerous patents for biomedical therapeutic
and diagnostic agents. He has published more than 300 scientific papers,
book chapters and abstracts, primarily related to treatment of cancer
and bone disease. He is a graduate of Emory University with a BS degree
in Chemistry, the Medical College of Georgia (MD), and Columbia
University School of Business (MBA). Profile
Genta?
Dr. Warrell: Genta is a biopharmaceutical company focused exclusively on
the development of new treatments for
